Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.

@article{LoRusso2012PhaseIS,
  title={Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.},
  author={Patricia M. LoRusso and Martin J. Edelman and Susan L Bever and Karen M. Forman and Maryjo Pilat and Mary F. Quinn and Jing Li and Elisabeth Heath and Lisa M Malburg and Patrick J. Klein and Christopher P. Leamon and Richard A. Messmann and Edward A. Sausville},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 32},
  pages={4011-6}
}
PURPOSE EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo. This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a bolus intravenous injection or 1-hour infusion in patients with refractory solid tumors. PATIENTS AND METHODS EC145 was administered as a bolus injection or 1-hour infusion on days 1, 3… CONTINUE READING